Latest news with #roboticSurgery
ABC News
5 days ago
- Health
- ABC News
Robotic surgery breakthrough for whistleblower doctors at Orange Hospital
Whistleblower doctors at a major regional New South Wales hospital have secured a breakthrough after they warned of delays to cancer surgeries and screening. One of the doctors' key concerns was whether the Orange Health Service, or other health services across the local health district (LHD), would be able to continue performing certain operations because of the lack of robotic surgical equipment. Robotic surgery is now considered by some clinicians to be standard practice for some operations, such as prostate cancer. The doctors had been asking management to lead lobbying efforts for its purchase and installation, but were knocked back. The Western NSW LHD has now changed its stance. "As part of the development of the new CSP [clinical services plan], we are also reassessing the viability of delivering robotic-assisted surgical services within the district, which includes determining the best options for that type of service," LHD chief executive Mark Spittal said in a statement. A 7.30 investigation in May revealed that urgent operations at Orange Health Service (OHS) were being downgraded to avoid breaching waiting list targets. At the time the Western NSW LHD rejected the claims and said operations were not being re-categorised to prioritise waiting lists over patient care. But the NSW Health Minister Ryan Park ordered a review and called an urgent meeting with the doctors and executives from the LHD. NSW Health secretary Susan Pearce then held talks with senior clinicians in late July. "Western NSW Local Health District is following up on a range of issues raised by staff working at Orange Health Service," Mr Spittal said. Urological surgeon Clair Whelan, one of the doctors who raised concerns, said there had been great progress. "We're excited to be working with the LHD to continue to deliver gold standard surgical care," Dr Whelan said. "Rural patients deserve the same quality care as our metropolitan counterparts, without the added burden of leaving our support networks. The Australian Medical Association's (AMA) NSW branch was involved in the meetings between doctors and the minister, and welcomed the LHD's change of heart. "We think it's fantastic that more modern services like robotic surgery can be delivered by those who are skilled in that workforce … to give the patients the care closer to home and certainly in their local area," AMA NSW president Kathryn Austin said. The senior doctors had also warned the capacity of Orange Health Service was among the reasons surgeries were being postponed. "It's very important that we continue to make sure that NSW Health does everything to support the frontline doctors and nurses of our workforce, and investments in the workforce and the infrastructure in which they work needs to be a priority," Dr Austin said. "Hopefully small changes like this will show that that's what they are doing." Mr Spittal said the LHD was working to prepare a new 10-year clinical services plan for the hospital. He said it would consider whether additional beds were needed, and examine the broader health precinct to find out what was required to meet future health needs.
Yahoo
01-08-2025
- Business
- Yahoo
Intuitive Surgical, Inc. (ISRG) Installs 395 da Vinci Systems in Q2, Forecasts 17% Procedure Growth
We recently compiled a list of the Intuitive Surgical, Inc. is placed first on our list. Intuitive Surgical, Inc. (NASDAQ:ISRG) tops our list for being one of the best major stocks. It is known for its da Vinci robotic surgical systems and reported strong Q2 2025 results, highlighting continued growth and innovation in minimally invasive surgery. Revenue rose 21% year-over-year to $2.44 billion, driven by a 17% increase in procedure volumes and record placements of 395 da Vinci systems globally. Of these, 180 were the newer da Vinci 5 systems, up from 70 a year earlier. The total installed base expanded to 10,488 systems, a 14% increase. The da Vinci 5 rollout is central to the company's momentum. It recently received EU certification for adult and pediatric procedures across multiple specialties, and clearance in Japan for nearly all previously approved surgical areas, excluding cardiac. Additional approval for the system's force feedback technology is being pursued in Europe. A surgical prosthesis developed by the company on display in a medical laboratory. Intuitive Surgical, Inc. (NASDAQ:ISRG) updated its 2025 gross margin outlook to 66%, adjusting for tariff effects. The company also reaffirmed expectations for 15–17% global procedure growth this year, reflecting strong demand as hospitals address surgical backlogs and broaden access to robotic procedures. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
16-07-2025
- Business
- Yahoo
BTIG Raises Intuitive Surgical (ISRG) Price Target, Maintains Buy Rating
Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. BTIG analyst Ryan Zimmerman has raised the firm's price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $566 from $542 while reiterating a rating ahead of the company's second-quarter earnings report. The adjustment comes as part of a broader outlook on the MedTech sector, which has faced pressure in recent months. A medical team performing minimally invasive surgery with a da Vinci Surgical System. In a research note to clients, Zimmerman highlighted that healthcare lagged the broader market in Q2, with MedTech stocks continuing to struggle early into the third quarter. Concerns over Medicaid reductions and potential hospital closures, stemming from recent legislative changes, have cast a shadow over the group, contributing to cautious investor sentiment. BTIG believes, however, that these fears may be exaggerated. While the upcoming earnings season is expected to produce uneven results, the firm sees conditions that could support a rebound. Inflation remains contained, currency exchange rates have become more favorable, and equity markets are near record highs, all of which could provide a tailwind to medical technology names. Within this mixed backdrop, Intuitive Surgical, Inc. (NASDAQ:ISRG) stands out for its consistent performance and robust fundamentals. The maker of robotic-assisted surgical systems is seen as well-positioned to weather sector-specific concerns, justifying BTIG's upward revision. Investors will be watching closely to see if the company can deliver results strong enough to reinforce its premium valuation. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
02-07-2025
- Health
- Yahoo
New robotic technology launched in Glasgow hospital for knee replacements
A Glasgow-based private hospital has launched new robotic technology for knee replacement surgery. Ross Hall Hospital, part of Circle Health Group, is said to be the only private hospital in Scotland to offer the VELYS Robotic-Assisted Solution. Developed by Johnson & Johnson MedTech, the system is designed to improve patient outcomes with shorter hospital stays and greater post-surgery mobility. Mhairi Jefferies, executive director of Ross Hall Hospital, said: "We are delighted to be working with Johnson & Johnson MedTech to deploy the VELYS system at Ross Hall Hospital. Read more: Vile rapist sentenced after preying on two young girls "We know our patients are looking for faster recovery times and an improved quality of life post-surgery. "The arrival of this system promises to offer our patients the latest and best technology on their doorstep." The VELYS system works exclusively with the ATTUNE Knee System and is designed to improve post-operative stability and movement by preserving soft tissue around the knee joint. It uses CT-free technology to assist surgeons in placing implants more accurately, aiming for more predictable outcomes and a quicker return to mobility. The first procedure using the new technology was carried out on April 23.
Globe and Mail
18-06-2025
- Business
- Globe and Mail
ISRG vs BSX: Which Medical Device Stock Has More Room to Run?
In a healthcare landscape increasingly shaped by technology, two names that stand out for their innovation and long-term potential are Intuitive Surgical ISRG and Boston Scientific BSX. Both companies are at the forefront of minimally invasive procedures — Intuitive as the undisputed leader in robotic-assisted surgery, and Boston Scientific as a powerhouse in interventional medical devices. With growing demand for advanced surgical solutions and aging global populations driving healthcare needs, investors are eyeing these med-tech giants as attractive long-term plays. But, which stock offers more compelling upside right now? Let's break down the fundamentals, growth trajectories, and market positions of ISRG and BSX to find out which one deserves a place in your portfolio. ISRG & BSX: Price Performance Intuitive Surgical represents a high-growth, high-premium pure play on robotic-assisted surgery. Its exceptional performance and growth provide compelling upside, but investors must accept margin compression and valuation risk in the short-to-medium term. Boston Scientific offers broader exposure to medical device innovation, with reliable growth driven by cardiovascular and interventional segments. It trades at a more moderate valuation and may appeal to investors seeking growth with less volatility. The year-to-date price performance of Intuitive Surgical has not been impressive, likely due to tariff concerns and rising competition from Chinese robotic device makers. However, BSX has outperformed ISRG likely due to its diversified business as well as strong U.S. demand. Shares of ISRG have lost 1.9% year to date, while those of BSX have gained 13.9%. Market Position & Core Offerings Intuitive Surgical dominates the surgical robotics niche with its flagship da???Vinci system, which continues to gain traction globally — 367 new units placed in the first quarter of 2025 alone, leading to a 17% year-over-year increase in procedures. Boston Scientific, by contrast, operates across a broader landscape of interventional medical devices, from cardiovascular to neuromodulation. Its success with Farapulse pulsed field ablation and strong cardiovascular sales (+26% in first-quarter 2025) highlight its diversified growth drivers. Growth & Performance ISRG delivered robust first-quarter 2025 results: revenues grew 19% to $2.25 billion, adjusted net income rose 22% to $767.5 million, and adjusted EPS grew 21% to $1.81. Its projected procedure growth remains strong at 15-17% for the year, though margins may be pressured by tariffs. BSX also posted solid first-quarter 2025 earnings, with adjusted EPS of $0.75 and sales worth $4.66 billion, both beating expectations on the back of cardiovascular and medical-surgical divisions. For the second quarter of 2025, revenues are expected to grow by double digits, driven by PFA and other interventions. Estimates Comparison for ISRG & BSX The Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 6.8%, respectively. EPS estimates for 2025 and 2026 have trended southward over the past 60 days. ISRG Estimate Movement The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. Moreover, EPS estimates for 2025 and 2026 have improved over the past 60 days. BSX Estimate Movement Cash & Cash Flow Intuitive Surgical maintains an exceptionally strong balance sheet, with $4.51 billion in cash and no debt as of the first quarter of 2025. The company generated free cash flow of around $465 million and operating cash flow of $582 million, driven by continued growth in da Vinci system procedures and high-margin recurring revenues from instruments and accessories. Boston Scientific, operates with a more leveraged profile. The company reported $725 million in cash and $11.31 billion in total debt, with a debt-to-equity ratio of nearly 50%. Despite this, BSX maintains strong cash generation, posting $541 million in operating cash flow and $354 million in free cash flow for the first quarter of 2025 alone. Its diversified product base, especially in cardiovascular and electrophysiology, supports ongoing growth and debt service. Risks & Operational Challenges ISRG is exposed to geopolitical and trade-related tariff risks — especially a 125% tariff on Chinese exports — which have led to margin revisions for 2025. Mitigation efforts include supply-chain adjustments and pricing flexibility. BSX contends with regulatory and legal exposures (notably from past medical-device recalls and mesh product lawsuits), but its diversified supply chain and global footprint help buffer macroeconomic pressures. ISRG or BSX: Which Is a Better Bet? For investors focused on explosive, category-leading growth in surgical robotics, ISRG may still be the superior choice. But those who prefer balanced exposure across med-tech segments with a steadier valuation profile might consider BSX as a more diversified, resilient option. Intuitive Surgical stands out for its pristine balance sheet, zero debt, and strong free cash flow, making it an appealing choice for investors prioritizing financial stability and growth. Boston Scientific's leveraged balance sheet is offset by a diversified product base and solid, consistent cash generation, positioning it as a resilient and innovative med-tech player for investors comfortable with moderate financial risk. Both companies currently carry a Zacks Rank #3 (Hold). However, if we go by the Zacks Style Score, BSX seems to be a better bet compared to ISRG. While ISRG has a Zacks Style Score of 'D', BSX's score is 'C', reflecting better growth potential. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
